<DOC>
	<DOCNO>NCT01626209</DOCNO>
	<brief_summary>Dose escalation study dose expansion phase , evaluate safety , tolerability , pharmacokinetics preliminary efficacy two dose level BKM120 administer orally .</brief_summary>
	<brief_title>A Phase I Study BKM120 Adult Chinese Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This single arm study , start dose BKM120 80mg/day . Two dose level : 80mg/day 100mg /day test dose escalation phase . At least 3 patient enrol dose level least 6 evaluable patient require treat recommended Phase II dose ( RP2D ) /MTD dose . After dose escalation 80mg/day 100mg /day dose level expand evaluate approximately total 15 patient ( 100mg determine RP2D/MTD ) .</detailed_description>
	<criteria>Patients histologicallyconfirmed , advance unresectable breast cancer advance carcinoma squamous cell histology ( include NSCLC , SCCHN , esophageal ) progress ( able tolerate ) standard therapy standard anticancer therapy exist Patient must provide representative archival fresh tumor biopsy ship Novartis designate laboratory profiling . Note : one block ≥ 15 unstained slide require determine PI3K activation status . Whenever possible ≥ 20 unstained slide prefer . Patient measurable and/or nonmeasurable disease per RECIST v1.1 guideline solid tumor Patient adult ( female male ) ≥ 18 year age day consent signature Patient Eastern Cooperative Oncology Group performance status ( ECOG PS ) ≤ 2 Patient receive previous treatment PI3K inhibitor Patient symptomatic CNS metastases Patients asymptomatic CNS metastasis may participate trial . The patient must complete prior local treatment CNS metastases ≥ 14 day prior start study treatment ( include radiotherapy and/or surgery ) . If patient receive ongoing corticosteroid therapy , follow criterion must meet : The patient must receive stable decrease dose ≤ dexamethasone 4 mg/day equivalent antiinflammatory potency another corticosteroid The dose corticosteroid may escalate least 14 day start study treatment Patient currently receive increase chronic treatment corticosteroid ( &gt; dexamethasone 4 mg equivalent antiinflammatory potency another corticosteroid ) another immunosuppressive agent . Note : Topical application ( e.g. , rash ) , inhale spray ( e.g. , obstructive airway disease ) , eye drop local injection ( e.g. , intraarticular ) allow . Patients previously treat asymptomatic brain metastasis , permit use corticosteroid per specific protocol criterion Patient currently receive treatment drug know moderate strong inhibitor inducer isoenzyme CYP3A . The patient must discontinue strong inducer least one week must discontinue strong inhibitor treatment initiate . Switching different medication prior start study treatment allow . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Breast cancer , NSCLC , SCCHN , esophageal cancer</keyword>
</DOC>